Fiacitabine is a pyrimidine nucleoside analog with activity against various herpesviruses. It is converted to its triphosphate form in vivo and inhibits viral DNA polymerase. It has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.
Fiacitabine is an antiviral compound and a selective inhibitior of DNA replication of herpes simplex virus(HSV).
The preparation method for Fecitabine involves using 2-deoxy-2-fluoro-tribenzoyl-α-D-arabinofuranose as the raw material. The arabinofuranose is brominated with the hydrobromic acetic acid solution under normal room temperature conditions to obtain 2-deoxy-2-fluoro-tribenzoyl-α-D-brominated arabinofuranose. Next, cytosine is used as the raw material for iodination and is Bz-protected to obtain -(5-Iodo-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide, which serves as the final intermediate. After the reaction, deprotection is carried out to obtain Fecitabine with a total yield as high as 43%.
Fiacitabine is an antimicrobial agent that inhibits microbial growth by binding to the ribosomal 30S subunit and blocking protein synthesis. It is a prodrug that is converted to 5-fluorocytosine (5FC) in the liver, where it inhibits the activity of the enzyme dihydropyrimidine dehydrogenase, thereby interfering with DNA replication.
